Natera executive sells shares for RSU tax withholding

Natera, Inc.January 20, 2026, he sold 23,205 shares of common stock at $234.7384 per share, leaving 144,992 shares beneficially owned directly after that transaction.

Rhea-AI Filing Summary

Natera, Inc.January 20, 2026, he sold 23,205 shares of common stock at $234.7384 per share, leaving 144,992 shares beneficially owned directly after that transaction. On January 21, 2026, he sold an additional 293 shares at $235.00 per share, with 144,699 shares beneficially owned directly afterward.

The footnotes state that both sales were effected to satisfy tax withholding and remittance obligations arising from the vesting of restricted stock units granted on January 27, 2023 and January 28, 2022, under written instructions intended to meet the affirmative defense conditions of Rule 10b5‑1(c) under the Exchange Act.

Insider Trade Summary

Net Seller: 23,498 shares

Net Sell 2 txns

Insider Moshkevich Solomon

Role PRESIDENT, CLINICALDIAGNOSTICS

Sold 23,498 shs ($5.52M)

Type	Security	Shares	Price	Value
Sale	Common Stock	293	$235.00	$69K
Sale	Common Stock	23,205	$234.7384	$5.45M

Holdings After Transaction: Common Stock — 144,699 shares (Direct)

Footnotes (2)

1. F1. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023.
2. F2. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 28, 2022.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider involved in this NTRA Form 4 filing?

The reporting person is Solomon Moshkevich, who serves as President, Clinical Diagnostics at Natera, Inc. (NTRA).

How many Natera (NTRA) shares did Solomon Moshkevich sell on January 20, 2026?

On January 20, 2026, Solomon Moshkevich sold 23,205 shares of Natera common stock at a price of $234.7384 per share.

What transaction did Solomon Moshkevich report on January 21, 2026 for Natera (NTRA)?

On January 21, 2026, he reported a sale of 293 shares of Natera common stock at a price of $235.00 per share.

How many Natera (NTRA) shares does Solomon Moshkevich hold after these transactions?

Following the January 21, 2026 transaction, Solomon Moshkevich beneficially owned 144,699 shares of Natera common stock held directly.

Why were the Natera (NTRA) shares sold by Solomon Moshkevich?

The footnotes state that both sales were made to satisfy tax withholding and remittance obligations in connection with the vesting of restricted stock units granted on January 27, 2023 and January 28, 2022.

Were the Natera (NTRA) share sales under a Rule 10b5-1 trading plan?

Yes. The filing notes that the sales were made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5‑1(c) under the Exchange Act contained in the reporting person's stock unit agreements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/22/2026 - 09:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TX 78753

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		23,205(1)	D	$234.7384	144,992	D
Common Stock	01/21/2026		S		293(2)	D	$235	144,699	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023.

2. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 28, 2022.

	/s/ Tami Chen, Attorney-in-Fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.